🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. Cesium-131 brachytherapy

    GT Biopharma

    Recurrent Brain Metastases

    phase 2 other active

    1 trial

  2. Cethrin

    Vertex Pharmaceuticals (Australia) Pty.

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  3. Chidamide

    Biotech Pharmaceutical Co.,

    Relapsed or Refractory Peripheral T-cell Lymphoma

    phase 2 small molecule active

    1 trial

  4. Chidamide

    Biotech Pharmaceutical Co.,

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule terminated

    1 trial

  5. Chlorambucil

    Teva Pharma GmbH

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  6. Chlorid sodný B. Braun 0,9 % infuzní roztok, DUOFAG

    Lacuna Pharma Pty Ltd

    Surgical wound infection/dehiscence caused by S. aureus and/or P. aeruginosa colonization

    phase 2 small molecule active

    1 trial

  7. Choice Of the Most Active Strategies for Short term recurring Triple Negative Breast Cancer A phase Ib/II, open-label, modular, dose-finding and dose-expansion study to explore safety, tolerability, pharmacokinetics, and anti-tumor activity of novel therapeutics in patients with early relapsed metastatic triple-negative breast cancer

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  8. ChronVac-C + SOC

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C

    phase 2 small molecule active

    1 trial

  9. Citanest® Dental Octapressin 30 mg/ml + 0,03 IE/ml, Xylocain ®Dental adrenalin 20 mg/ml + 12,5 mikrog/ml Injeksjonsvæske, oppløsning i sylindretter

    Lacuna Pharma Pty Ltd

    Subjects having local anesthesia for dental procedures.

    phase 2 small molecule active

    1 trial

  10. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  11. Clifutinib Besylate

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acute Myeloid Leukemia, Adult

    phase 2 small molecule active

    1 trial

  12. Clonazepam

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  13. Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP, JNJ-64407564, JNJ-64407564, Clonazepam Orally Disintegrating Tablets, USP, Pregabalin-ratiopharm® 25 mg Hartkapseln, Pregabalin-ratiopharm® 50 mg Hartkapseln, Clonazepam Orally Disintegrating Tablets, USP, DEXAMETHASONE ELIXIR, USP, Clonazepam Orally Disintegrating Tablets, USP, Clonazepam Orally Disintegrating Tablets, USP

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 2 small molecule active

    1 trial

  14. Coagulation Factor IX variant

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia B

    phase 2 mab completed

    1 trial

  15. Coagulation Factor VIIa variant

    CATALYST PHARMACEUTICALS, INC.

    Factor VII Deficiency

    phase 2 mab terminated

    1 trial

  16. Coagulation Factor VIIa variant

    CATALYST PHARMACEUTICALS, INC.

    Hemophilia A With Inhibitor

    phase 2 mab completed

    1 trial

  17. Cohort A: ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule completed

    1 trial

  18. Coronary Artery Stenting

    Medtronic BioPharma B.V.

    Coronary Artery Disease

    phase 2 other completed

    1 trial

  19. Crofelemer Placebo Powder for Oral Solution

    Lacuna Pharma Pty Ltd

    Microvillous Inclusion Disease (MVID)

    phase 2 small molecule active

    1 trial

  20. Crystalline Lactulose

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy

    phase 2 small molecule completed

    1 trial

  21. Cyclobenzaprine HCl

    Tonix Pharmaceuticals Holding

    Acute Stress Reaction

    phase 2 small molecule active

    1 trial

  22. Cyclophosphamide

    Karyopharm Therapeutics Inc

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  23. Cyproterone acetate 5

    Teva Pharma GmbH

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  24. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Leukemia

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources